Drug Profile
Research programme: kidney disease therapeutics - Amgen/Galapagos
Latest Information Update: 08 Sep 2008
Price :
$50
*
At a glance
- Originator ProSkelia
- Developer Amgen; Galapagos NV
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Kidney disorders
Most Recent Events
- 08 Sep 2008 Discontinued - Preclinical for Kidney disorders in USA (unspecified route)
- 22 Dec 2006 Galapagos NV acquires ProStrakan's responsibilities for this research collaboration, as part of Galapagos' purchase of ProSkelia
- 07 Aug 2006 Preclinical trials in Kidney disorders in USA (unspecified route)